Global

Ireland has built a track record of regulatory excellence that few regions have matched.

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy.

The U.S. government’s contract with Shionogi highlights renewed public-private investment in antimicrobial resistance and biodefense, aiming to strengthen domestic manufacturing and expand the role of novel antibiotics against high-priority threats.

Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.

Members of PacBio and iHope discuss collaboration and the global state of genomic testing.

Conflict in the Middle East is forcing pharmaceutical companies to reroute temperature-sensitive medicines through alternative corridors.

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

In this video episode, Pratap Khedkar, PhD, CEO of ZS, joins the Pharm Exec Podcast to discuss three distinct industry trends and strategy shifts converging at the moment amid the backdrop of US-driven global policy change.

Following the decisions=, the European Commission decided to close a long-running antitrust investigation

Most medical digital pilots are designed for success in controlled conditions.

The shifting landscape amid China's biotech rises presents both opportunities and geopolitical challenges for growth strategies.

The outlook highlights major progress in reducing U.S. breast cancer deaths through improved screening and treatment, while noting that rising incidence and ongoing disparities continue to challenge patients and the health care system.

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

The preservative, which contains a form of Mercury, has long been the target of anti-vaccine groups, despite studies demonstrating its safety.

Global pharmaceutical production surged in 2025 due to tariff-driven front-loading but is expected to slow as trade uncertainty, patent expirations, pricing pressure, and shifting industrial policy reshape the industry’s growth, investment, and supply chain strategies.

The decision is based on President Trump’s executive order issued last year.

The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.

Welcome to Pharm Exec's new guest column on navigating the geopolitical risks challenging core company strategies in today's shifting global landscape for healthcare.

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

The stock increased after positive Q3 earnings and deals with the Trump administration.

The Swiss region hopes to attract pharma companies looking to escape uncertainty in the US market.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

Eli Lilly invests $1.2 billion in Puerto Rico to enhance manufacturing capabilities, creating jobs and integrating advanced technologies for oral medicines.

President Trump’s latest attempt at implementing International Reference Pricing- based (IRP-) methodology to regulate drug prices in the US has the broadest and strictest scope.

Ypsomed invests $250 million in a new U.S. manufacturing facility, enhancing local supply and creating jobs in Holly Springs, North Carolina.